Akari Therapeutics annual stock-based compensation
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Akari Therapeutics Stock-Based Compensation Growth & History (AKTX)
Akari Therapeutics's stock-based compensation was $2.9M for fiscal 2025.
View full Akari Therapeutics company overviewAkari Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.9M | $645,000 | +28.73% |
| 2024 | 2024-12-31 | $2.2M | $1.1M | +95.22% |
| 2023 | 2023-12-31 | $1.1M | $415,000 | +56.46% |
| 2022 | 2022-12-31 | $735,000 | $420,350 | +133.59% |
| 2021 | 2021-12-31 | $314,650 | −$10,873 | −3.34% |
| 2020 | 2020-12-31 | $325,523 | −$721,864 | −68.92% |
| 2019 | 2019-12-31 | $1.0M | −$601,657 | −36.49% |
| 2018 | 2018-12-31 | $1.6M | −$1.1M | −39.70% |
| 2017 | 2017-12-31 | $2.7M | −$1.2M | −30.47% |
| 2016 | 2016-12-31 | $3.9M | $2.9M | +278.24% |
| 2015 | 2015-12-31 | $1.0M | $1.0M | — |
| 2014 | 2014-12-31 | $0 | −$94,000 | — |
| 2013 | 2013-12-31 | $94,000 | −$420,000 | −81.71% |
| 2012 | 2012-12-31 | $514,000 | $374,000 | +267.14% |
| 2011 | 2011-12-31 | $140,000 | $140,000 | — |
| 2010 | 2010-12-31 | $0 | −$70,000 | — |
| 2009 | 2009-12-31 | $70,000 | −$98,000 | −58.33% |
| 2008 | 2008-12-31 | $168,000 | −$280,000 | −62.50% |
| 2007 | 2007-12-31 | $448,000 | $379,000 | +549.28% |
| 2006 | 2006-12-31 | $69,000 | −$50,000 | −42.02% |
| 2005 | 2005-12-31 | $119,000 | — | — |
Akari Therapeutics quarterly stock-based compensation
Q1.14
Q2.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q1.19
Q2.19
Q1.20
Q2.20
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $711,000 | −$8,000 | −1.11% |
| Q1 2026 | 2026-03-31 | $305,000 | −$710,000 | −69.95% |
| Q4 2025 | 2025-12-31 | $471,000 | −$785,000 | −62.50% |
| Q3 2025 | 2025-09-30 | $685,000 | $437,000 | +176.21% |
| Q2 2025 | 2025-06-30 | $719,000 | $274,000 | +61.57% |
| Q1 2025 | 2025-03-31 | $1.0M | $719,000 | +242.91% |
| Q4 2024 | 2024-12-31 | $1.3M | $952,000 | +313.16% |
| Q3 2024 | 2024-09-30 | $248,000 | −$57,000 | −18.69% |
| Q2 2024 | 2024-06-30 | $445,000 | $169,000 | +61.23% |
| Q1 2024 | 2024-03-31 | $296,000 | $31,000 | +11.70% |
| Q4 2023 | 2023-12-31 | $304,000 | — | — |
| Q3 2023 | 2023-09-30 | $305,000 | — | — |
| Q2 2023 | 2023-06-30 | $276,000 | — | — |
| Q1 2023 | 2023-03-31 | $265,000 | — | — |
| Q2 2020 | 2020-06-30 | $63,330 | −$346,292 | −84.54% |
| Q1 2020 | 2020-03-31 | $100,504 | −$293,935 | −74.52% |
| Q2 2019 | 2019-06-30 | $409,622 | — | — |
| Q1 2019 | 2019-03-31 | $394,439 | — | — |
| Q2 2016 | 2016-06-30 | $805,406 | $805,406 | — |
| Q1 2016 | 2016-03-31 | $816,805 | $816,805 | — |
| Q4 2015 | 2015-12-31 | $963,804 | — | — |
| Q3 2015 | 2015-09-30 | $76,062 | — | — |
| Q2 2015 | 2015-06-30 | $0 | −$156,000 | — |
| Q1 2015 | 2015-03-31 | $0 | −$195,000 | — |
| Q2 2014 | 2014-06-30 | $156,000 | — | — |
| Q1 2014 | 2014-03-31 | $195,000 | — | — |
Akari Therapeutics stock-based compensation trends
Over the last five fiscal years, Akari Therapeutics's stock-based compensation increased from $325,523 to $2.9M, a change of $2.6M. The latest reported quarter, Q2 2026, shows $711,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akari Therapeutics source filings ↗